AVI Partners With Karolinska

Xconomy Seattle — 

AVI Biopharma (NASDAQ: AVII), the Bothell, WA-based developer of RNA-targeted therapies, said today it has formed a collaboration with leading scientists at the Karolinska Institute in Sweden to find new treatments for extensively drug resistant forms of tuberculosis known as XDR-TB. Funding and research support is provided by both parties, and intellectual property resulting from the work will be jointly owned, AVI said in a statement. AVI retains an exclusive right to acquire Karolinska’s interest in intellectual property, AVI said.